Daiichi Sankyo Company, Limited - Product Pipeline Review - 2014

Published: Nov, 2014 | Pages: 164 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Daiichi Sankyo Company, Limited - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Daiichi Sankyo Company, Limited - Product Pipeline Review - 2014', provides an overview of the Daiichi Sankyo Company, Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Daiichi Sankyo Company, Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Daiichi Sankyo Company, Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Daiichi Sankyo Company, Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Daiichi Sankyo Company, Limited's pipeline products

Reasons to buy

- Evaluate Daiichi Sankyo Company, Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Daiichi Sankyo Company, Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Daiichi Sankyo Company, Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Daiichi Sankyo Company, Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Daiichi Sankyo Company, Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Daiichi Sankyo Company, Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Daiichi Sankyo Company, Limited Snapshot 6
Daiichi Sankyo Company, Limited Overview 6
Key Information 6
Key Facts 6
Daiichi Sankyo Company, Limited - Research and Development Overview 7
Key Therapeutic Areas 7
Daiichi Sankyo Company, Limited - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Partnered Products 15
Pipeline Products - Out-Licensed Products 17
Daiichi Sankyo Company, Limited - Pipeline Products Glance 19
Daiichi Sankyo Company, Limited - Late Stage Pipeline Products 19
Daiichi Sankyo Company, Limited - Clinical Stage Pipeline Products 22
Daiichi Sankyo Company, Limited - Early Stage Pipeline Products 24
Daiichi Sankyo Company, Limited - Drug Profiles 26
edoxaban tosylate 26
levofloxacin 28
methylene blue 29
CL-108 30
denosumab 31
etanercept biosimilar 34
hydromorphone hydrochloride 35
KIB-PCI 36
mirogabalin 37
nimotuzumab 38
patritumab 41
prasugrel hydrochloride 43
tivantinib 45
VN-0103 48
VN-100 49
CS-3150 50
DS-8500 51
efatutazone 52
exatecan mesylate 54
laninamivir 56
tigatuzumab 58
DS-1040 60
DS-1093 61
DS-1150b 62
DS-1971 63
DS-3032 64
DS-3078 65
DS-3801 66
DS-5573a 67
DS-6051 68
DS-7423 69
DS-8273 70
DS-8895 71
Small Molecule to Inhibit Ubiquitin Ligase for Cancer 72
U3-1565 73
Antibody Drug Conjugate for Solid Tumors 75
CS-1050 76
DC-159a 77
DF-461 78
DS-1558 79
DS-8108b 80
Monoclonal Antibodies for Undisclosed Indication 81
PN1-Ab 82
Protein for Undiscosed Indication 83
Recombinant Proteins 2 for Undisclosed Indication 84
RS-1269 85
Small Molecule for Respiratory Tract Infections 86
Small Molecule to Agonize PPAR Alpha and PPAR Gamma for Metabolic Disorders 87
Small Molecule to Agonize PPAR Gamma Receptor for Type 2 Diabetes 88
Small Molecule to Inhibit I-KappaB Kinase Beta for Rheumatoid Arthritis 89
Small Molecule to Inhibit PDE4 for COPD 90
Small Molecule to Inhibit PDE4B for Lung Inflammation 91
Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis 92
Small Molecule to Inhibit VLA-4 for Asthma 93
Small Molecules to Inhibit FATP1 for Undisclosed Indication 94
Small Molecules to Inhibit p53-MDM2 Interaction for Cancer 95
Small Molecules to Inhibit Renin for Hypertension 96
SQ-641 97
U3-1784 98
Antisense Oligonucleotide for Duchenne Muscular Dystrophy 99
Beta-Cell Regeneration Program 100
Drugs for Cancer 101
Drugs for Oncology, Cardiovascular and Metabolic Diseases 102
DS-5272 103
Pedopeptins to Inhibit LPS for Bacterial Infection 104
Small Molecule for Cardiovascular-Metabolic Diseases 105
Small Molecule for Tuberculosis 106
Small Molecule to Inhibit CTP synthase for Respiratory Tract Infections 107
Small Molecules for Malaria 108
Small Molecules for Multiple Neurodegenerative Diseases 109
Small Molecules for Osteopenia and Osteoporosis 110
Small Molecules to Agonize BRS-3 for Undisclosed Indication 111
Sphaerimicin A 112
U-31201 113
U-31910 114
U-31987 115
Daiichi Sankyo Company, Limited - Pipeline Analysis 116
Daiichi Sankyo Company, Limited - Pipeline Products by Target 116
Daiichi Sankyo Company, Limited - Pipeline Products by Route of Administration 120
Daiichi Sankyo Company, Limited - Pipeline Products by Molecule Type 121
Daiichi Sankyo Company, Limited - Pipeline Products by Mechanism of Action 123
Daiichi Sankyo Company, Limited - Recent Pipeline Updates 126
Daiichi Sankyo Company, Limited - Dormant Projects 145
Daiichi Sankyo Company, Limited - Discontinued Pipeline Products 146
Discontinued Pipeline Product Profiles 147
Daiichi Sankyo Company, Limited - Company Statement 152
Daiichi Sankyo Company, Limited - Locations And Subsidiaries 153
Head Office 153
Other Locations & Subsidiaries 153
Daiichi Sankyo Company, Limited - Key Manufacturing Facilities 156
Appendix 157
Methodology 157
Coverage 157
Secondary Research 157
Primary Research 157
Expert Panel Validation 157
Contact Us 158
Disclaimer 158

List of Tables
Daiichi Sankyo Company, Limited, Key Information 12
Daiichi Sankyo Company, Limited, Key Facts 12
Daiichi Sankyo Company, Limited - Pipeline by Indication, 2014 14
Daiichi Sankyo Company, Limited - Pipeline by Stage of Development, 2014 19
Daiichi Sankyo Company, Limited - Monotherapy Products in Pipeline, 2014 20
Daiichi Sankyo Company, Limited - Partnered Products in Pipeline, 2014 21
Daiichi Sankyo Company, Limited - Partnered Products/ Combination Treatment Modalities, 2014 22
Daiichi Sankyo Company, Limited - Out-Licensed Products in Pipeline, 2014 23
Daiichi Sankyo Company, Limited - Out-Licensed Products/ Combination Treatment Modalities, 2014 24
Daiichi Sankyo Company, Limited - Pre-Registration, 2014 25
Daiichi Sankyo Company, Limited - Filing rejected/Withdrawn, 2014 26
Daiichi Sankyo Company, Limited - Phase III, 2014 27
Daiichi Sankyo Company, Limited - Phase II, 2014 28
Daiichi Sankyo Company, Limited - Phase I, 2014 29
Daiichi Sankyo Company, Limited - Preclinical, 2014 30
Daiichi Sankyo Company, Limited - Discovery, 2014 31
Daiichi Sankyo Company, Limited - Pipeline by Target, 2014 123
Daiichi Sankyo Company, Limited - Pipeline by Route of Administration, 2014 126
Daiichi Sankyo Company, Limited - Pipeline by Molecule Type, 2014 128
Daiichi Sankyo Company, Limited - Pipeline Products by Mechanism of Action, 2014 130
Daiichi Sankyo Company, Limited - Recent Pipeline Updates, 2014 132
Daiichi Sankyo Company, Limited - Dormant Developmental Projects,2014 151
Daiichi Sankyo Company, Limited - Discontinued Pipeline Products, 2014 152
Daiichi Sankyo Company, Limited, - Other Locations 159
Daiichi Sankyo Company, Limited, - Subsidiaries 159
Daiichi Sankyo Company, Limited, - Key Manufacturing Facilities 162